Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

CB1093, a novel vitamin D analog; effects on differentiation and clonal growth on HL-60 and de novo leukemia cells.

Pakkala I, Savli H, Knuutila S, Binderup L, Pakkala S.

Leuk Res. 1997 Apr;21(4):321-6.

PMID:
9150349
2.

1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.

Jung SJ, Lee YY, Pakkala S, de Vos S, Elstner E, Norman AW, Green J, Uskokovic M, Koeffler HP.

Leuk Res. 1994 Jun;18(6):453-63.

PMID:
8207963
3.
4.

Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.

Pakkala S, de Vos S, Elstner E, Rude RK, Uskokovic M, Binderup L, Koeffler HP.

Leuk Res. 1995 Jan;19(1):65-72.

PMID:
7837819
5.
6.

19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.

Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler HP.

Cancer Res. 1998 Aug 1;58(15):3370-5.

7.

20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.

Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.

Anticancer Res. 1999 May-Jun;19(3A):1689-97.

PMID:
10470102
8.

The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.

Shany S, Levy Y, Lahav-Cohen M.

Steroids. 2001 Mar-May;66(3-5):319-25.

PMID:
11179740
9.
10.

Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.

Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, Mais DE, Bissonnette RP, Heyman RA, Nadzan AM, Reichman M, Allegretto EA.

Chem Biol. 1999 May;6(5):265-75.

11.
12.

24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.

Shiohara M, Uskokovic M, Hisatake J, Hisatake Y, Koike K, Komiyama A, Koeffler HP.

Cancer Res. 2001 Apr 15;61(8):3361-8.

13.

Antiproliferative effect of a vitamin D3 analog, EB1089, on HL-60 cells by the induction of TGF-beta receptor.

Jung CW, Kim ES, Seol JG, Park WH, Lee SJ, Kim BK, Lee YY.

Leuk Res. 1999 Dec;23(12):1105-12.

PMID:
10613355
14.

Effects of 1,25(OH)2D3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88.

Kunakornsawat S, Rosol TJ, Capen CC, Middleton RP, Hannah SS, Inpanbutr N.

Anticancer Res. 2001 Sep-Oct;21(5):3355-63.

PMID:
11848494
15.

Sensitive induction of apoptosis in breast cancer cells by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity.

Danielsson C, Mathiasen IS, James SY, Nayeri S, Bretting C, Hansen CM, Colston KW, Carlberg C.

J Cell Biochem. 1997 Sep 15;66(4):552-62.

PMID:
9282333
16.

Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts.

Lee YY, Kim ES, Seol JG, Kim BK, Binderup L, Elstner E, Park DJ, Koeffler HP.

Leukemia. 1996 Nov;10(11):1751-7.

PMID:
8892678
17.

EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells.

Mathiasen IS, Colston KW, Binderup L.

J Steroid Biochem Mol Biol. 1993 Sep;46(3):365-71.

PMID:
9831485
18.

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.

Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.

Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):241-8.

20.

Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.

Danilenko M, Wang X, Studzinski GP.

J Natl Cancer Inst. 2001 Aug 15;93(16):1224-33.

PMID:
11504768

Supplemental Content

Support Center